Skip to main content

GS-US-419-3895 Combined Phase 3, Double-blind, Randomized, Placebo-Controlled
Studies Evaluating the Efficacy and Safety of Filgotinib in the
Induction and Maintenance of Remission in Subjects with Moderately
to Severely Active Crohn’s Disease

NCT02914561

Combined Phase 3, Double-blind, Randomized, Placebo-Controlled
Studies Evaluating the Efficacy and Safety of Filgotinib in the
Induction and Maintenance of Remission in Subjects with Moderately
to Severely Active Crohn’s Disease

Associated Conditions

Inflammatory Bowel Disease (IBD)

Principal Investigator

Sponsor

Gilead Sciences

You have been asked to be part of this study because you have been diagnosed with Crohn’s disease, which is an inflammatory disease of the gastrointestinal tract (digestive tract). The purpose of this study is to see if filgotinib is effective and safe in treating people with moderate to severe Crohn’s disease

This study is currently enrolling.